Comparative Pharmacology
Head-to-head clinical analysis: CLOTIC versus ELOCON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLOTIC versus ELOCON.
CLOTIC vs ELOCON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clotrimazole is an imidazole antifungal that inhibits ergosterol synthesis by inhibiting 14α-demethylase (CYP51), leading to disruption of fungal cell membrane integrity and increased permeability.
Elocon (mometasone furoate) is a synthetic corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It binds to the glucocorticoid receptor, leading to increased synthesis of lipocortins that inhibit phospholipase A2, thereby reducing arachidonic acid release and subsequent prostaglandin and leukotriene formation. It also suppresses cytokine production and inflammatory cell migration.
Topical: Apply a thin layer to affected areas 2-4 times daily. Duration limited to 2 weeks; maximum 50 g/week. Intralesional: 0.5-1 mL of 10 mg/mL solution injected into lesion weekly.
Apply a thin film to affected skin area once daily. Use no more than 45 g per week.
None Documented
None Documented
Terminal elimination half-life is 3.5 hours (range 2.5-4.5 h) in adults with normal renal function; extends to 6-8 hours in mild-moderate renal impairment.
Terminal elimination half-life approximately 5-7 hours after topical application. Systemic half-life is short, limiting systemic accumulation with topical use.
Renal: 65% as unchanged drug; biliary/fecal: 20% as metabolites; remainder as inactive conjugates.
Primarily hepatic metabolism; metabolites excreted renally and in feces. Approximately 60% of a topical dose is excreted in urine as metabolites, 30% in feces.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid